Natalie Ma is an entrepreneur working to build a better future for humanity on Earth and in space through biotechnology. She currently serves as the Director of Business Development at Felix Biotechnology, a phage technology company developing therapies to life-threatening, drug-resistant bacterial infections. Felix Bio’s precision therapy approach to phage not only kills pathogens and treats infections, but also drives evolution of remaining pathogen populations to become sensitive to antibiotics and less dangerous to humans. Prior to Felix, Natalie was a Blavatnik Fellow at Yale University, where she worked with faculty to develop the commercial value story of their discoveries and launch startups. Prior to this, she was a Consultant at ClearView Healthcare Partners, developing commercial strategies for therapies in oncology, rare disease, and infectious disease for biotech and pharma companies.
Natalie holds a B.S. in Environmental Science and a PhD in Molecular Biology, with a particular focus on synthetic biology. In her free time, she pursues projects seeking to launch humankind into permanent space settlement and to understand the interplay between biological breakthroughs and global security, as well as cultivating a passion for foraged and wild food.